← Back to Search

Aftercare Treatment for Obsessive-Compulsive Disorder

N/A
Waitlist Available
Led By Carolyn Rodriguez, MD, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Children younger than 18
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 14 weeks
Awards & highlights

Summary

This trial is for OCD patients who have completed a different study protocol and are now looking for aftercare treatment options.

Who is the study for?
This trial is for adults with Obsessive Compulsive Disorder (OCD) who have finished a previous study at the Rodriguez Lab. They must understand the risks and benefits of this study, be able to consent, and speak English. It's not open to anyone under 18 or those currently having thoughts of suicide.
What is being tested?
The trial offers ongoing treatment options for OCD through pharmacotherapy (medication) and psychotherapy (counseling). It's designed for patients from prior studies at the Rodriguez Lab to continue receiving care and support.
What are the potential side effects?
While specific side effects are not listed here, generally, medications can include nausea, headache, sleep disturbances or mood changes; psychotherapy might bring up uncomfortable emotions but is usually safe.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 14 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 14 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)

Trial Design

2Treatment groups
Active Control
Group I: PharmacotherapyActive Control1 Intervention
Participants will receive pharmacotherapy by a psychiatrist
Group II: PsychotherapyActive Control1 Intervention
Participants will receive evidenced based psychotherapy by a trained psychologist

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,448 Previous Clinical Trials
17,492,194 Total Patients Enrolled
15 Trials studying Obsessive-Compulsive Disorder
1,203 Patients Enrolled for Obsessive-Compulsive Disorder
Carolyn Rodriguez, MD, PhDPrincipal Investigator - Assistant Professor, Stanford University
Stanford University
6 Previous Clinical Trials
113 Total Patients Enrolled
3 Trials studying Obsessive-Compulsive Disorder
97 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Pharmacotherapy Clinical Trial Eligibility Overview. Trial Name: NCT03511534 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Pharmacotherapy, Psychotherapy
Obsessive-Compulsive Disorder Clinical Trial 2023: Pharmacotherapy Highlights & Side Effects. Trial Name: NCT03511534 — N/A
Pharmacotherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT03511534 — N/A
~17 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top